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Abstract: Whole-exome sequencing (WES) is a new tool that allows the rapid, inexpensive 
and accurate exploration of Mendelian and complex diseases, such as obesity. To identify 
sequence variants associated with obesity, we performed WES of family trios of one male 
teenager and one female child with severe early-onset obesity. Additionally, the teenager 
patient had hypopituitarism and hyperprolactinaemia. A comprehensive bioinformatics 
analysis found de novo and compound heterozygote sequence variants with a damaging 
effect on genes previously associated with obesity in mice (LRP2) and humans (UCP2), 
among other intriguing mutations affecting ciliary function (DNAAF1). A gene ontology 
and pathway analysis of genes harbouring mutations resulted in the significant identification of 
OPEN ACCESS
Genes 2014, 5 710
overrepresented pathways related to ATP/ITP (adenosine/inosine triphosphate) metabolism 
and, in general, to the regulation of lipid metabolism. We discuss the clinical and 
physiological consequences of these mutations and the importance of these findings for 
either the clinical assessment or eventual treatment of morbid obesity. 
Keywords: DNAAF1; genetics; leptin-melanocortin; LRP2; megalin; monogenic; obesity; 
pituitary; UCP2; whole-exome sequencing 
 
1. Introduction
Obesity is a global epidemic: the World Health Organization (WHO) estimates that half a billion 
people over the age of twenty worldwide are obese [1]. Global projections estimate that worldwide,  
1.2 billion individuals will be obese by 2030 [2]. 
Obesity and its related traits have high estimates of heritability (h2 between 40% and 70%) [3].  
The investigation of candidate genes and genome-wide association studies have identified more than 
60 obesity susceptibility genes that predispose to increased body weight, waist circumference,  
waist-hip ratio, body mass index (BMI) and fat percentage or fat mass. However, mutations in these 
genes account for a very small fraction of the obesity phenotypic variance [4,5]. It has been estimated 
that at least 7% of children with severe early-onset obesity (defined by an onset before the age  
of 10 years and BMI over three standard deviations (SD) above normal) have a single locus sequence 
variant determining obesity [6]. Nine susceptibility genes, determinants of non-syndromic Mendelian 
forms of human obesity, are involved in the hypothalamic control of energy balance via the  
leptin-melanocortin pathway and/or in neural development [4]: brain-derived neurotrophic factor 
(BDNF), leptin (LEP), leptin receptor (LEPR), melanocortin-4 receptor (MC4R), neurotrophic tyrosine 
kinase receptor type 2 (NTRK2), prohormone convertase 1 (PCSK1), proopiomelanocortin (POMC), 
single-minded homolog 1 (SIM1) and, more recently, melanocortin 2 receptor accessory protein 2 
(MRAP2) [7]. 
Exome sequencing is rapidly becoming the first-line approach for monogenic disorders [8]. The use 
of whole-exome capture and the complete sequencing of the coding genome of parent-child trios is a 
highly effective approach for identifying homozygous, compound heterozygous and de novo coding 
sequence variants, as multiple de novo sequence variants occurring within a specific gene (or within a 
gene family or pathway) are extremely implausible events [8]. Its rationale is based on the fact that 
gene variants located in exons are more likely to be pathogenic than those located in introns or 
between genes. The power of this strategy has increased with the access to large numbers of publicly 
available exome sequences that allow the controlled comparison of frequencies, as well as the 
identification of de novo variants and stratification by ethnicity. This strategy has been used to identify 
candidate genes for several Mendelian and complex traits [9–12]. In the assessment of obesity,  
whole-exome sequencing has identified sequence variants in the leptin receptor gene [13], in the 
ADCY3 gene [14] and in the BBIP1 gene in patients with Bardet–Biedl syndrome [15]. However, no 
novel pathogenic genes or pathways associated with obesity have been identified through this 
approach yet.  
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In this study, by employing whole-exome capture and sequencing in the assessment of two patients 
with severe early-onset obesity (and their parents), we identified de novo mutations and the compound 
heterozygous status of several damaging variants. Intriguingly, some of these variants were harboured 
in genes involved in the pathophysiology of obesity (such as LRP2 and UCP2), providing the foundation 
for future research in this field. Thus far, we emphasize that the networking of clinical case-reports and 
genetic analyses would be crucial to finding the major loci underpinning complex disorders.  
2. Experimental 
Two family trios, the probands of which had severe early-onset obesity (onset before the age of  
10 years and BMI over three SD above normal) were included in this study. All parents and capable 
patients provided written informed consent for the genetic research studies, which were performed in 
accordance with the study protocol approved by the Australian National University Human Research 
Ethics Committee (Protocol 2011/108, approved on the 6 May, 2011) and in concordance with the 
Helsinki Declaration of 1975, as revised in 2008. DNA was extracted from peripheral blood from the 
patients and parents for genetic analysis. 
2.1. DNA Library Preparation, Exome Capture and Sequencing Protocol 
Libraries were constructed from 1 g of genomic DNA using an Illumina TruSeq genomic DNA 
library kit (Illumina Inc., San Diego, CA, USA). Libraries were multiplexed with 6 samples pooled 
together (500 ng of each library). Exons were enriched from the pooled 3 g of library DNA using an 
Illumina TruSeq Exome enrichment kit (Illumina Inc.). Each exome-enriched pool was run on a  
100-base-pair paired-end run on an Illumina HiSeq 2000 sequencer (Illumina Inc.). We surveyed 
201,071 genomic regions in total using the exome capture platform. Ninety percent of the bases in 
approximately 197,000 of these targeted regions had at least one read coverage. All regions were 
sampled at approximately 50× coverage. 
2.2. Sequence Read Processing, Alignment, Bioinformatics and Genetic Analyses 
The sequencing image data were processed in real time using Illumina Real Time Analysis (RTA) 
software (Illumina Inc.) and converted to fastq files containing DNA base calls (A, C, G and T) and 
quality scores using the Illumina CASAVA pipeline (a software program that converts raw image data into 
sequences). The resulting fastq files were further processed for variant analysis. 
The entire workflow of data curation and analysis for variant-calling was developed by the Genome 
Discovery Unit (GDU) at The Australian National University. Key components of the workflow 
include: (i) quality assessment; (ii) read alignment; (iii) local realignment around the known and novel 
indel regions to refine indel boundaries; (iv) recalibration of base qualities; (v) variant calling; and  
(vi) assigning quality scores to variants (detailed workflow information is in the Supplemental Material).  
Subsequently, we included a filtering phase (using information from dbSNP and the 1K Exome 
Project), with the following sequential steps: (1) identification of rare or de novo variants (a lower 
minor allele frequency cut-off (MAF) in the window of 0.1%–1.0%); (2) filtering of variants to include 
those that are potentially pathogenic or are specific variants associated with disease susceptibility 
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using several tools, namely, SIFT, PolyPhen2, Mutation Taster, Mutation Assessor and Functional 
Analysis through Hidden Markov Models (FATHMM), as implemented by the DNA-seq Analysis 
Package (SVS7.7.6, Golden Helix, Bozeman, MT, USA) (variants were not excluded if classified as 
potentially damaging by at least one of these filtering tools); (3) filtering of damaging variants based 
on genes known to be associated with human disease; and (4) independent confirmation of selected 
variants by Sanger sequencing (Supplemental Material). The definition of de novo sequence variants, 
compound heterozygous polymorphisms and rare recessive homozygous polymorphisms was 
performed with different modules of the DNA-seq Analysis Package (SVS7.7.6, Golden Helix, 
Bozeman, MT, USA). 
To identify potential enriched endocrine-physiological pathways, a genetic ontology pathway 
analysis was performed. For constructing the pathways, variants with potential functional changes 
detected by the de novo and the compound heterozygous analysis were examined with the set of 
algorithms implemented in MetaCore (Thomson Reuters, New York, NY, USA) for the heuristic 
interpretation of maps, networks and rich ontologies for diseases. 
3. Clinical Reports
Patient 1: A Brazilian male teenager with a history of excessive weight gain starting at age 3, 
decelerated growth since age 11 and delayed puberty was first evaluated at age 14 y, 3 m. His body 
weight was 105.0 kg (+5.32 SD score), his height 152.5 cm (1.45 SD score) and his BMI  
45.2 kg/m2 (+11.03 SD score) (Figure 1). The patient had no complaints of hearing deficits or vision 
loss. Testicular volumes were <2 mL bilaterally, and he was at Tanner pubertal stage P2–P3. He had 
cubitus valgus and round facies. During physical examination, profuse sweating was noted. Other 
physical signs were unremarkable. 
Figure 1. Height, weight and BMI of Patient 1, from birth to age 15 y, 10 m. 
 A B
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Figure 1. Cont.
 
Growth charts illustrating changes in height (A), weight (B) and BMI (C). M, maternal height; P, paternal height; 
TH, target height. From WHO Child Growth Standard: Methods and Developments. 
Obesity was a common finding in his family, but all individuals had normal height. His father is 
obese (BMI 36.7 kg/m2), as are his paternal grandfather (BMI 44.6 kg/m2) and paternal uncle  
(BMI 50.5 kg/m2). His mother’s BMI is 30.1 kg/m2, and two maternal aunts are also obese  
(BMI 31.6 and 30.1 kg/m2). His older brother is overweight (BMI 29 kg/m2). None of his family 
members have a history of severe early-onset obesity. There was no history of consanguinity in the 
family. Pregnancy was uneventful, and size at birth was 4.2 kg and 51.5 cm.  
He had been previously diagnosed with central hypothyroidism at age 9, with thyroid-stimulating 
hormone (TSH) of 7.4 mU/L and free T4 of 9.5 pmol/L, with undetectable titres of antithyroglobulin 
and antithyroperoxidase antibodies and a normal thyroid ultrasound. He also had elevated serum 
prolactin levels of 2,908 pmol/L, measured for the first time at age 9. Magnetic resonance enhanced by 
the contrast gadolinium showed a pituitary gland of normal volume, with no evidence of pituitary 
adenoma and without any structural abnormalities in the brain. The search for macroprolactin was 
negative (71% recovery after polyethylene glycol precipitation). He had been on treatment with 
levothyroxine 88 g/day since age 9 y, 5 m, and cabergoline 0.5 mg every 10–15 days since age 13 y, 2 m, 
which had normalized his serum TSH and prolactin levels. 
During the previous five years, he was treated with hypocaloric mixed diets, frequent physical 
activity, sibutramine 10 mg/day and orlistat 120 mg after meals. This approach resulted in only a 6-kg 
noncontinuous weight loss.  
The patient’s serum triglycerides and total cholesterol were elevated (3.11 and 4.84 mmol/L, 
respectively), with low HDL-cholesterol of 0.85 mmol/L and normal calculated LDL-cholesterol of 
1.99 mmol/L. Fasting plasma glucose and insulin were 5.33 mmol/L and 13 U/mL, respectively, with 
the homeostasis model assessment-estimated insulin resistance (HOMA-IR) index equal to 3.07. His 
serum insulin-like growth factor 1 (IGF-1) level was below the age reference range (71.25 nmol/L; 
reference value 130–563 nmol/L). Growth hormone (GH) secretion was evaluated during a standard 
C
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insulin provocative test, with no development of hypoglycaemia during the test (lowest glucose level 
of 3.55 mmol/L and respective GH level of 0.06 g/L). Morning cortisol and adrenocorticotropic 
hormone (ACTH) levels were normal (0.68 mol/L and 1.60 pmol/L, respectively). His serum leptin 
levels were 8.1 and 18.0 g/L at age 9 and appropriately elevated at age 13 (69.7 g/L). At age 13, his 
total testosterone levels were pre-pubertal (0.90 nmol/L), and follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) were undetectable. At age 13 y, 9 m, his bone age was 15.6 years. Table 1 
summarizes the laboratory test results and their respective reference range values.  
Table 1. Laboratory test results for Patient 1.  
Test Value Normal reference range 
Thyroid-stimulating hormone (TSH) * 7.4 mU/L 0.3–5.0 mU/L 
Free T4 * 9.5 pmol/L 10.3–25.7 pmol/L 
Antithyroglobulin (ATG) and 
antithyroperoxidase (ATPO) antibodies * 
Both negative 
<9.0 IU/mL (ATG) 
<116 IU/mL (ATPO) 
Prolactin * 2908 pmol/L 82–504 pmol/L 
Macroprolactin * Negative (71% recovery) >50% recovery 
Total cholesterol $ 4.84 mmol/L 4.4 mmol/L 
HDL cholesterol $ 0.85 mmol/L >1.16 mmol/L 
LDL cholesterol $ 1.99 mmol/L <2.84 mmol/L 
Triglycerides $ 3.11 mmol/L <1.02 mmol/L 
Fasting plasma glucose $ 5.33 mmol/L 3.89–5.5 mmol/L 
Fasting insulin $ 13 U/mL 1.8–4.6 U/mL 
Insulin-like growth factor 1 (IGF-1) & 71.25 nmol/L 130–563 nmol/L 
Growth hormone (GH)/glucose &# 0.06 g/L/3.55 mmol/L >5 g/L/<1.94 mmol/L 
Adrenocorticotropic hormone (ACTH) 
(morning) 
1.60 pmol/L 2.2–13.2 pmol/L 
Cortisol (morning) 0.68 mol/L 0.14–0.70 mol/L 
Leptin 8.1 * and 69.7 g/L & Detectable 
Total testosterone & 0.90 nmol/L 3.47–41.60 nmol/L 
Follicle-stimulating hormone (FSH) & Undetectable 0.5–10.5 IU/L 
Luteinizing hormone (LH) & Undetectable 0.5–7.9 IU/L 
Total calcium ^ 2.62 mmol/L 2.40–2.64 mmol/L 
Inorganic phosphate ^ 173.4 mmol/L 108.4–164.2 mmol/L 
Magnesium ^ 1.1 mmol/L 0.7–0.9 mmol/L 
Alkaline phosphatise ^ 114 U/L 66–571 U/L 
25-hydroxy vitamin D ^ 85 mmol/L >75 mmol/L 
Parathyroid hormone (PTH) ^ 2.6 pmol/L 1.0–5.5 pmol/L 
Selenium @ 0.03 mol/L 0.25–2.4 mol/L 
Total urinary protein @ 0.08 g/24 hours <0.15 g/24 hours 
* Measured at age 9, not treated with levothyroxine and cabergoline; $ measured at age 12; # GH and lowest 
glucose level measured during a standard insulin provocative test; & measured at age 13; ^ measured at age 14; 
@ measured at age 16. 
Radiographic studies showed lumbar scoliosis convex to the right, mild reduction of intervertebral 
spaces at L4-S1, mild shortening of L1, as well as a short fourth metacarpal. In order to exclude the 
diagnosis of Albright’s hereditary osteodystrophy, serum electrolytes, alkaline phosphatase, vitamin D 
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and parathyroid hormone (PTH) were measured, which were all unremarkable for Albright’s 
hereditary osteodystrophy (total calcium 2.62 mmol/L; inorganic phosphate 173.4 mmol/L; 
magnesium 1.1 mmol/L, alkaline phosphatase 114 U/L, 25-hydroxy vitamin D 85 mmol/L and PTH 
2.6 pmol/L). His serum levels of selenium were 0.03 mol/L, 10-fold lower than the lowest limit of the 
normal range (reference values 0.25–2.4 mol/L). Total urinary protein levels were 0.08 g/24 hours.  
Intramuscular injections of testosterone esters (70 mg every four weeks) were initiated for puberty 
induction. Biosynthetic GH was initiated in a dose of 0.33 mg/day and increased to 0.66 mg/day 
according to IGF-1 levels. Four months after starting GH therapy, he developed episodes of fever of 
unexplained origin, which resolved spontaneously after six months. During that period, investigation  
for infection disease was negative, including a normal PET-scan, with leucocytosis as the only 
observed abnormality.  
Patient 2: A two year-old Brazilian girl was evaluated for severe early-onset obesity. Her body 
weight was 23 kg (+4.79 SD score), her height was 93 cm (+2.32 SD score) and her BMI  
was 26.6 kg/m2 (+4.49 SD score). She was born with 2.9 kg and 46 cm, from an uneventful pregnancy. 
Excessive weight gain was noted upon a few weeks after birth. Neurologic development was normal, 
with no evidence of Prader–Willi or Bardet–Biedl syndromes. She had normal serum leptin levels  
of 18 g/L. A history of recurrent bacterial and viral respiratory tract infections was noted, which 
warranted the need for antibiotic therapy almost every month. There was no significant familial history 
of obesity or consanguinity. The physical examination was unremarkable.
4. Results 
We called a total of 455,342 variants, 336,652 of them polymorphic, 21,613 matched at the 
dbNSFP, 12,286 with potential pathogenic effects and 2,291 with a minor allele frequency <1% when 
compared to the 1 kG phase 1. Our filtering approach by de novo functional mutation screening 
reported three de novo sequence variants with a potential damaging effect (Table 2). These sequence 
variants were found in Patient 1 (UCP2) and in Patient 2 (AICDA and FAM71E2). 
The compound heterozygous analysis identified 20 variants with potential functional effects 
associated with eight genes, namely: LRP2, AMPD3, OR8U8-OR9G1 and SLC22A6 in Patient 1 and
TTN, APEH, DNAAF1 and KIR3DL3 in Patient 2 (Table 3). From a literature search on the compound 
heterozygous variants that were classified as damaging, we identified two sequence variants in the 
LRP2 gene that may potentially affect LRP2 protein function in Patient 1: a genomic variant GT 
(NC_000002.11:g.170009391G>T), resulting in a nonsynonymous substitution on codon 4127 
(NM_004525.2:c.12379C>A; NP_004516.2:p.Arg4127Ser), and a genomic variant CT 
(NC_000002.11:g.170030506C>T), resulting in a nonsynonymous substitution on codon 3646 
(NM_004525.2:c.10937G>A; (NP_004516.2:p.Arg3646His). The LRP2 gene encodes a multi-ligand 
endocytic receptor (also known as megalin or glycoprotein 330) involved in the regulation of the 
leptin-melanocortin pathway.  
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Table 2. De novo damaging sequence variants. 
Patient Variant Chr Position Ref All
Alt
All Identifier Classification Gene Transcript Exon HGVS Coding 
HGVS
Protein 
1 11:73689104-SNV 11 73,689,104 G A rs660339 Nonsyn SNV UCP2 NM_003355 4 c.164C>T p.Ala55Val 
2 12:8757523-Ins 12 8,757,523 - A rs5796316 Splicing AICDA NM_020661 4 c.428-5_428-4insT  
2 19:55873642-SNV 19 55,873,642 C T rs4252574 Nonsyn SNV FAM71E2 NM_001145402 3 c.535G>A p.Glu179Lys 
Chr: chromosome; Ref All: reference allele; Alt All: alternate allele; HGVS: Human Genome Variation Society nomenclature. 
Table 3. Sequence rare variants (allele frequency in the general population <1%) with potential damaging effect by compound heterozygous analysis. 
Patient Single Nucleotide Variant Chromosome Position Identifier Gene 
dbSNP MAF 
Frequency Alleles
Reference 
Allele
Reference 
Aminoacid 
Altered
Aminoacid
HGVS
Protein 
1 2:170009391-SNV 2 170009391 rs148356370 LRP2 0.005 G/T G R S p.R4127S 
1 2:170030506-SNV 2 170030506 rs142549310 LRP2 0.002 C/T C R H p.R3646H 
1 11:10518373-SNV 11 10518373 rs144107914 AMPD3 0.001 C/T C S L p.S323L 
1 11:10527316-SNV 11 10527316 N/A AMPD3 *** A/G G R Q p.R571Q 
1 11:56468198-SNV 11 56468198 rs4990194 OR8U8-OR9G1 0.069 A/G A Y C p.Y112C 
1 11:56468212-SNV 11 56468212 rs591369 OR8U8-OR9G1 ** A/G G V M p.V117M 
1 11:56468554-SNV 11 56468554 rs12420076 OR8U8-OR9G1 0.061 A/C A K Q p.K231Q 
1 11:56468560-SNV 11 56468560 rs10896516 OR8U8-OR9G1 ** C/T T Y H p.Y233H 
1 11:56468561-SNV 11 56468561 rs10896517 OR8U8-OR9G1 0.047 A/G A Y C p.Y233C 
1 11:62748503-SNV 11 62748503 rs150409056 SLC22A6 * G/T G R S p.R331S 
1 11:62749384-SNV 11 62749384 rs200609617 SLC22A6 *** C/T C A T p.A243T 
2 2:179507021-SNV 2 179507021 N/A TTN *** G/A G R C p.R4436C 
2 2:179577628-SNV 2 179577628 N/A TTN *** C/T C V I p.V7798I 
2 2:179634421-SNV 2 179634421 rs200875815 TTN *** T/G T T P c.8749A>C 
2 3:49716372-SNV 3 49716372 N/A APEH *** A/G G R H p.R383H 
2 3:49720698-SNV 3 49720698 N/A APEH *** A/G G A T p.A708T 
2 16:84203467-SNV 16 84203467 rs143322223 DNAAF1 *** C/G C E Q p.E345Q 
2 16:84208329-SNV 16 84208329 rs139519641 DNAAF1 * A/G A ? ? Splicing 
2 19:55239223-SNV 19 55239223 rs117372288 KIR3DL3 *** A/G A V I p.V168I 
2 19:55241240-SNV 19 55241240 rs111516669 KIR3DL3 ** A/G A V I p.V313I 
Note: The first two rows show the sequence variants that affect function, harboured at the LRP2 gene (NC_000002.11:g.170009391G>T and 
NC_000002.11:g.170030506C>T). N/A: not available. * Monomorphic in available data from dbSNP database; ** MAF only available for 2 chromosomes; *** There is 
no frequency data. 
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Sanger sequencing of the two amplicons containing the two LRP2 sequence variants validated the 
findings obtained from the whole-exome capture and sequencing analysis (Figure 2). These results 
confirmed that each parent is heterozygous for one of the sequence variants (the mother is 
heterozygous for the mentioned sequence variant (g/t) (NC_000002.11:g.170009391G>T), and the 
father is heterozygous for the sequence variant (c/t) (NC_000002.11:g.170030506C>T), whereas  
the patient is heterozygous for both LRP2 sequence variants. Therefore, the patient is compound 
heterozygous for the LRP2 gene as initially described in the whole-exome capture and sequencing 
analysis (Figure 2). 
Figure 2. Sanger sequencing results from Patient 1 and parents. 
 
Sanger sequencing of the LRP2 gene shows that both parents are heterozygous for  
one of the mutations. The mother is heterozygous for the Chr2:170009391 sequence variant  
(g/t) (NC_000002.11:g.170009391G>T), and the father is heterozygous for the Chr2: 170030506 variant 
(c/t) (NC_000002.11:g.170030506C>T). The patient is compound heterozygous and has both  
sequence variants. 
MetaCore analysis, including those genes harbouring functional mutations, namely UCP2, AICDA,
FAM71E2, TTN, APEH, DNAAF1, KIR3DL3, LRP2, AMPD3, OR8U8-OR9G1 and SLC22A6, defined 
six pathways significantly overrepresented (after false discovery correction, FDR), e.g.,: (1) ATP/ITP 
(adenosine/inosine triphosphate) metabolism; (2) regulation of lipid metabolism/peroxisome 
proliferator-activated receptor (PPAR) regulation of lipid metabolism; (3) development of insulin,  
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IGF-1 and TNF-alpha in brown adipocyte differentiation; (4) mitochondrial dysfunction in 
neurodegenerative diseases; (5) oxidative stress role of Sirtuin1 and PGC1 alpha in the activation of 
the defence system; and (6) CTP/UTP (cytidine/uridine triphosphate) metabolism (Table 4). 
Table 4. Significant pathways from MetaCore analysis of candidate morbid obesity genes. 
Pathways of Candidate Morbid Obesity Genes 
Genes from Input 
List in Pathway 
p-Value FDR 
ATP, ITP metabolism AMPD3 1.107e-3 6.640e-3 
Regulation of lipid metabolism PPAR regulation of lipid 
metabolism
UCP2 1.851e-2 3.164e-2 
Development of insulin, IGF-1 and TNF-alpha in brown 
adipocyte differentiation 
UCP2 2.332e-2 3.164e-2 
Mitochondrial dysfunction in neurodegenerative diseases UCP2 2.594e-2 3.164e-2 
Oxidative stress role of Sirtuin1 and PGC1 alpha in the 
activation of the defence system 
UCP2 2.637e-2 3.164e-2 
CTP UTP metabolism AICDA 4.709e-2 4.709e-2 
Note: p-values and false discovery (FDR) correction adjusting for multiple comparisons, representing the 
probability that these pathways generated from our candidate gene list would appear by coincidental chance 
from feeding a random set of genes.  
5. Conclusions 
In this study, by employing whole-exome capture and sequencing, we identified novel sequence 
variants in the LRP2 gene that might be associated with the phenotype of severe early-onset obesity in 
Patient 1. Similar to the other genes associated with monogenic forms of obesity, LRP2 is also 
involved in the regulation of the leptin-melanocortin pathway [16]. In addition, in Patient 1, we found 
a de novo sequence variant in the UCP2 gene, a transporter protein present in the mitochondrial inner 
membrane that is a key regulator of energy balance, the variants of which have already been associated 
with obesity [17]. In Patient 2, we identified sequence variants in the DNAAF1 gene, which might be 
related to the second patient’s phenotype. The DNAAF1 gene is required for the stability of the ciliary 
architecture, and it has been demonstrated that ciliary dysfunction is associated with the pathogenesis 
of obesity [18,19]. 
Recently, LRP2 has been nominated as a novel appetite regulator responsible for generating satiety 
signals in hypothalamic neurons [16]. It is a multiligand endocytic receptor, a member of the low 
density lipoprotein receptor gene family, which binds a large variety of ligands. Leptin is one of its 
ligands; LRP2 mediates its reuptake in renal tubules [20] and promotes leptin transport across the 
choroid plexus [21]. LRP2 also binds to the long-form leptin receptor (LepRb), forming a complex  
that is co-localized and subjected to endocytosis in the hypothalamic neurons. Subsequently,  
the endocytosis of this co-localized complex leads to the activation of signal transducer and activator 
of transcription 3 (STAT3) signalling in hypothalamic neurons, including proopiomelanocortin 
(POMC)- and LepRb-expressing neurons. As a consequence, food intake and body weight are 
decreased. In the absence of functional LRP2, STAT3 signalling is decreased. Therefore, hunger is 
stimulated and satiety decreased [16]. 
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The binding of LRP2 and LepRb is enhanced by clusterin, a sulphated glycoprotein widely 
expressed in hypothalamic areas involved in the regulation of food intake and energy metabolism [22]. 
Chronic intracerebroventricular (icv) administration of clusterin causes the reduction of food intake, 
body weight and epididymal fat mass [16]. LRP2 is expressed in rodent hypothalamus, and its 
inhibition by small interfering RNA significantly blunts the effects of clusterin icv injections on food 
intake and Stat3 activation [16]. Therefore, LRP2 acts as a key mediator of the food intake-suppressing 
effects of clusterin, and its absence can cause obesity in rodents (as previously demonstrated) [16].  
Sequence variants in the LRP2 gene have been previously associated with Donnai–Barrow/facio-
oculo-acoustico-renal (DB/FOAR) syndrome [23]. The phenotype of this syndrome includes agenesis 
of the corpus callosum, developmental delay, enlarged anterior fontanelle, high myopia, hypertelorism, 
proteinuria and sensorineural hearing loss, but not obesity. In a review by Pober et al., sensorineural 
hearing loss, high myopia and proteinuria were present in 100% of DB/FOAR syndrome cases. None 
of those features were present in Patient 1; therefore, we ruled this diagnosis out. Serum selenium 
levels in patients with DB/FOAR syndrome have not been reported, but it has been shown that LRP2 
mediates the reuptake of selenoproteins in the kidney and that LRP2-mutant mice have low selenium 
serum levels due to the increased urinary excretion of selenoproteins [24]. Since the patient’s serum 
levels of selenium were 10-fold lower than those of the reference range, this finding supports the 
impairment of the biological function of LRP2.  
Besides suffering from severe early-onset obesity, Patient 1 also had pituitary dysfunction characterized 
by GH deficiency, central hypothyroidism and hypogonadotropic hypogonadism, with concomitant 
hyperprolactinaemia. It is unclear whether sequence variants in the LRP2 gene can directly affect 
pituitary development and function. LRP2 is essential for brain development [25], as knock-out mice 
exhibit holoprosencephaly [26] and Lrp2-mutant mice have abnormal cortical axon development [27]. 
Humans with DB/FOAR syndrome have structural brain abnormalities, mainly agenesis of the corpus 
callosum and, in one reported case, empty sella turcica [28]. These support the hypothesis that LRP2 
sequence variants might lead to abnormalities in pituitary development and hypopituitarism.  
In addition, Patient 1 had a de novo variant in the UCP2 gene. As a transporter protein that is 
expressed in the mitochondrial inner membrane, UCP2 decreases mitochondrial ATP production by 
mediating H+ leak across the inner membrane [17]. Patient 1 has a G to A substitution at rs660339, 
resulting in an Ala55Val substitution, which has been associated with obesity in diverse settings [29,30]. 
Moreover, polymorphisms at rs660339 may also affect metabolic efficiency in terms of energy 
expenditure [31]. It is noteworthy to mention that this de novo variant has a reported minor allele 
frequency of about 0.5% and that it is a site that mutates recurrently.  
The other de novo sequence variants that we found in Patient 2 (AICDA, Activation-Induced 
Cytidine Deaminase; and FAM71E2, Family with Sequence Similarity 71, Member E2) are protein 
coding genes for a RNA-editing deaminase and for a protein of unknown function, respectively.  
The variant rs5796316 in AICDA has been reported in one previous study. Whereas AICDA is 
possibly not implicated in the pathophysiology of obesity, the function of FAM71E2 is unknown to 
date. However, rs4252574 in FAM71E2 is quite common, and the variant A allele is the major allele 
reported at about 70%.  
In Patient 2, we did not find gene variants that would strongly explain the phenotype, as we did for 
Patient 1. However, we identified sequence variants harboured in the DNAAF1 that are possibly 
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implicated in the patient’s history of recurrent infections and severe obesity. That gene is responsible 
for encoding a protein that is cilium-specific and is required for the stability of the ciliary architecture. 
DNAFF1 is one of the 21 genes in which mutations are associated with primary ciliary dyskinesia 
(PCD) [32]. It is unlikely that Patient 2 has PCD, given the absence of its clinical manifestations 
(bronchiectasis, defects in body situs and, later in life, infertility). However, it is possible that 
identified DNAAF1 sequence variants are causing a milder form of PCD with recurrent airway 
infections and severe obesity. Ciliary dysfunction has been associated with severe early-onset obesity, 
and currently, it is known that two obesity syndromes are caused by mutations in genes regulating 
ciliary function: Bardet–Biedl syndrome and Alström syndrome [19]. It has been demonstrated that 
ciliary dysfunction leads to the development of obesity in animal models, due to diverse alterations in 
central and peripheral pathways regulating energy metabolism [18,33–38]. For Patient 2, electron 
microscopy would be useful in the assessment of the effect of the DNAAF1 gene variant on ciliary 
structure. Furthermore, as we have not confirmed the DNAAF1 variant by Sanger sequencing, we cannot 
confirm that it is in trans in the patient (i.e., each parent contributing one of the variants). 
It is unlikely that the other gene variants with potential damaging effect (Table 3) also play a role in  
the pathogenesis of obesity, since they are not related to the regulation of the leptin-melanocortin pathway. 
Particularly, TTN is a large gene, the variants of which are frequently unrelated to disease; and  
OR8U8-OR9G1, the variants of whichmost likely represent artefacts, possibly due to alignment problems.  
By performing MetaCore pathway analysis of the genes harbouring functional mutations, we 
observed that six pathways are significantly overrepresented, all of them involving energy or 
ATP/ITP/CTP/UCP metabolism. The importance of UCP2 on energy metabolism was further 
strengthened by the observation that four of these pathways were centred on the UCP2 gene.  
In whole-genome association studies (GWAS), the LRP2 and the DNAAF1 genes were previously 
associated with increased BMI in a British population, without reaching a level of significance that is 
relevant for GWAS [39]. Curiously, a higher significance level for a single nucleotide polymorphism 
(SNP) within the LRP2 gene (p = 8.68 × 106) was found in a GWAS of patients with anorexia  
nervosa [40]. Although variants at UCP2 rs660339 have been associated with increased BMI in 
Europeans [41], this finding was not replicated in a recent meta-analysis in populations representing 
four ethnicities [42].  
Whole-exome capture and sequencing can be used with family-based phenotype ascertainment 
strategies (nuclear and extended families) to exploit parent-child transmission and relative-relative 
sharing/not sharing patterns, as well as with arbitrary strategies of phenotype dichotomization to 
increase efficiency. In an extreme phenotype study design, individuals who are at both ends of a 
phenotype distribution are selected for sequencing. It is assumed that alleles contributing to the trait in 
individuals who are at both ends of the phenotype distribution are enriched, and sequencing even a 
modest sample size can potentially identify novel candidate alleles. The same consideration is also 
applicable to additional alternatives aimed to identify de novo variants that involve the sequencing of  
parent-offspring trios in which only the offspring is affected. The clinical use of whole-exome capture 
and sequencing is promising, as demonstrated in a recent study that evaluated 250 patients with 
undiagnosed diseases: the success rate in obtaining a genetic diagnosis was as high as 25% in  
that study [12].  
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Recently, guidelines for investigating and reporting the causality of sequence variants in human 
disease have been published, to avoid an acceleration of false-positive reports of causality [43]. In our 
study, we comply with those guidelines, but we acknowledge that our findings are not sufficient to 
implicate those gene variants as determinants of the obese phenotype. The significance of our results can 
be limited due to the fact that the number of probands is very small. However, a similar approach has 
already been validated and published by other studies, such as the Finding of Rare Disease Genes 
(FORGE) Canada Consortium [44]. In addition, WES has been applied for the diagnosis of several 
diseases, as observed in many case reports with very small sample sizes [45]. Furthermore, despite the 
fact that our results have not been replicated yet in other obese individuals, they are important to raise 
awareness of the LRP2 gene as a possible candidate as a novel monogenic cause of obesity. In addition, 
our results lack confirmation through functional data, which should be pursued in future studies.  
Whole-exome capture and sequencing analysis is a time- and resource-intense endeavour. 
Currently, we employ software that allows rapid selection of any genetic variant according to variant 
type, novelty (via screening public and private databases) and predicted protein effect. However, 
linking these results to phenotypic manifestations in a particular person is currently performed by a 
mixture of manual analysis using a number of additional databases (e.g., Human Genome Mutation 
Database, Online Mendelian Inheritance in Man (OMIM), PubMed and UCSC, among others). We 
built on existing analytic tools in order to rapidly detect and annotate genomic variants associated with 
human disease. We are aware that analytical criteria for filtering need to be flexible and up-to-date; 
therefore, we undertook a systematic upgrade and iterative processes of database evaluation by 
considering each filter. 
In conclusion, by employing a novel and unique strategy for whole-exome capture and sequencing 
analysis of two trios comprised of patients with severe early-onset obesity, we have identified 
sequence variants in the LRP2 and in the UCP2 genes that might explain the phenotype of a patient 
with severe early-onset obesity, central hypothyroidism, hypogonadotropic hypogonadism, growth 
hormone deficiency and idiopathic hyperprolactinaemia. In addition, we identified a sequence variant 
in the DNAAF1 gene that might be implicated in the development of severe obesity associated with 
ciliary dysfunction. Whereas de novo variants in the UCP2 gene have already been associated with 
obesity, the role of LRP2 and DNAAF1 sequence variants in human obesity needs to be further 
investigated by functional studies, and the frequency and distribution of those sequence variants need 
to be evaluated in a larger number of obese individuals. 
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